Phase 3 Clinical Trials With Primary Completion Dates in December 2024
This is a list of Phase 3 trials with primary completion dates in December 2024 for companies with a market cap less than $1B. For complete clinical trial coverage, please see our Trial Tracker tool. It includes information on all clinical trials for publicly traded companies, screenable by stock symbol, market cap, disease, completion date, and phase.
The primary completion date is the date that the final subject was examined or received an intervention for the purposes of final collection of data for the primary outcome. It provides advance notice that a company will be announcing trial results in the near future.
| Symbol | Company | Primary Completion Date | Phase | NCT ID | Title |
|---|---|---|---|---|---|
| ABSCF | AB Science S.A. | 2024-12-01 | Phase 3 | NCT04333108 | Masitinib in Severe Indolent or Smoldering Systemic Mastocytosis Unresponsive to Optimal Symptomatic Treatment |
| AGIO | Agios Pharmaceuticals, Inc. | 2024-12-01 | Phase 3 | NCT05175105 | A Study to Evaluate the Efficacy and Safety of Mitapivat in Pediatric Participants With Pyruvate Kinase Deficiency (PKD) Who Are Not Regularly Transfused, Followed by a 5-Year Extension Period |
| ASND | Ascendis Pharma A/S | 2024-12-01 | Phase 3 | NCT05171855 | A Trial to Investigate Long Term Efficacy and Safety of Lonapegsomatropin in Adults With Growth Hormone Deficiency |
| AUPH | Aurinia Pharmaceuticals Inc. | 2024-12-01 | Phase 3 | NCT05288855 | Voclosporin in Adolescents With Lupus Nephritis |
| AXSM | Axsome Therapeutics, Inc. | 2024-12-01 | Phase 3 | NCT05972044 | A Study to Access the Efficacy and Safety of Solriamfetol in Subjects With ADHD (FOCUS) |
| AXSM | Axsome Therapeutics, Inc. | 2024-12-01 | Phase 3 | NCT05550207 | Open-Label Study of AXS-07 for the Acute Treatment of Migraine in Adults With a Prior Inadequate Response to an Oral CGRP Inhibitor (EMERGE) |
| AXSM | Axsome Therapeutics, Inc. | 2024-12-01 | Phase 3 | NCT05113745 | A Study to Assess the Long-term Efficacy and Safety of AXS-12 (Reboxetine) in Subjects With Narcolepsy |
| AXSM | Axsome Therapeutics, Inc. | 2024-12-01 | Phase 3 | NCT04947553 | A Study to Assess the Long-term Safety and Efficacy of AXS-05 in Subjects With Alzheimer's Disease Agitation |
| BCDA | BioCardia, Inc. | 2024-12-01 | Phase 3 | NCT02438306 | CardiAMP™ Cell Therapy for Heart Failure Trial |
| BHVN | Biohaven Ltd. | 2024-12-01 | Phase 3 | NCT04641143 | Efficacy and Safety Study of Adjunctive Troriluzole in Obsessive Compulsive Disorder |
| BPMUF | Basilea Pharmaceutica AG | 2024-12-01 | Phase 3 | NCT05856227 | Late-onset Sepsis in Term and Pre-term Neonates and Infants up to 3 Months of Age |
| CADL | Candel Therapeutics, Inc. | 2024-12-01 | Phase 3 | NCT01436968 | Phase 3 Study of ProstAtak® Immunotherapy With Standard Radiation Therapy for Localized Prostate Cancer |
| CASBF | CanSino Biologics Inc. | 2024-12-01 | Phase 3 | NCT06131554 | A Clinical Trial to Evaluate the Immunogenicity and Safety of Group ACYW135 Meningococcal Conjugate Vaccine (CRM197) in Adults Aged 18 to 55 Years |
| CHJTF | CSPC Pharmaceutical Group Limited | 2024-12-01 | Phase 3 | NCT05783557 | A Study of Clevidipine Butyrate Injectable Emulsion in the Treatment of Hypertensive Emergency and Sub-emergency |
| CLVLY | Clinuvel Pharmaceuticals Limited | 2024-12-01 | Phase 3 | NCT06109649 | A Study to Compare the Efficacy and Safety of SCENESSE and Narrow-Band Ultraviolet (NB-UVB) Light Versus NB-UVB Light Alone in Patients With Vitiligo |
| CORT | Corcept Therapeutics Incorporated | 2024-12-01 | Phase 3 | NCT05257408 | Relacorilant in Combination With Nab-Paclitaxel in Advanced, Platinum-Resistant, High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian-Tube Cancer |
| EQ | Equillium, Inc. | 2024-12-01 | Phase 3 | NCT05263999 | A Study of Itolizumab in Combination With Corticosteroids for the First-Line Treatment of Acute Graft Versus Host Disease (EQUATOR) |
| FOLD | Amicus Therapeutics, Inc. | 2024-12-01 | Phase 3 | NCT04138277 | A Study to Assess the Long-term Safety and Efficacy of ATB200/AT2221 in Adult Subjects With LOPD |
| GLMD | Galmed Pharmaceuticals Ltd. | 2024-12-01 | Phase 3 | NCT04104321 | A Clinical Study to Evaluate the Efficacy and Safety of Aramchol in Subjects With NASH (ARMOR) |
| IMVT | Immunovant, Inc. | 2024-12-01 | Phase 3 | NCT05517421 | Study to Assess Batoclimab in Participants With Active Thyroid Eye Disease |
| IMVT | Immunovant, Inc. | 2024-12-01 | Phase 3 | NCT05524571 | Study to Assess Batoclimab in Participants With Active Thyroid Eye Disease |
| LBTSF | Almirall, S.A. | 2024-12-01 | Phase 3 | NCT06135415 | A Study to Evaluate the Efficacy and Safety of Tirbanibulin Ointment in Adult Participants With Actinic Keratosis |
| MEDP | Medpace Holdings, Inc. | 2024-12-01 | Phase 3 | NCT04979806 | Study of Cefepime-zidebactam (FEP-ZID) in Complicated Urinary Tract Infection (cUTI) or Acute Pyelonephritis (AP) |
| MLYS | Mineralys Therapeutics, Inc. | 2024-12-01 | Phase 3 | NCT06153693 | Efficacy and Safety of Lorundrostat in Subjects With Uncontrolled and Resistant Hypertension |
| NMRA | Neumora Therapeutics, Inc. | 2024-12-01 | Phase 3 | NCT06029426 | Study to Evaluate the Effects of Oral NMRA-335140 Versus Placebo in Participants With Major Depressive Disorder |
| NVCR | NovoCure Limited | 2024-12-01 | Phase 3 | NCT02831959 | Pivotal, Open-label, Randomized Study of Radiosurgery With or Without Tumor Treating Fields (TTFields) for 1-10 Brain Metastases From Non-small Cell Lung Cancer (NSCLC). |
| RARE | Ultragenyx Pharmaceutical Inc. | 2024-12-01 | Phase 3 | NCT05345171 | Clinical Study of DTX301 AAV- Mediated Gene Transfer for Ornithine Transcarbamylase(OTC) Deficiency |
| RARE | Ultragenyx Pharmaceutical Inc. | 2024-12-01 | Phase 3 | NCT05611528 | Safety and Effectiveness of Evinacumab for the Treatment of Homozygous Familial Hypercholesterolemia |
| REGMF | RemeGen Co., Ltd. | 2024-12-01 | Phase 3 | NCT04714190 | A Study of RC48-ADC in Local Advanced or Metastatic Gastric Cancer With the HER2-Overexpression |
| RLMD | Relmada Therapeutics, Inc. | 2024-12-01 | Phase 3 | NCT06011577 | Randomized, Double-Blind, Placebo-Controlled Trial of REL-1017 as Adjunctive Treatment for MDD |
| RLMD | Relmada Therapeutics, Inc. | 2024-12-01 | Phase 3 | NCT04855747 | A Study to Assess the Efficacy and Safety of REL-1017 as Adjunctive Treatment for Major Depressive Disorder (MDD) |
| SLS | SELLAS Life Sciences Group, Inc. | 2024-12-01 | Phase 3 | NCT04229979 | Galinpepimut-S Versus Investigator's Choice of Best Available Therapy for Maintenance in AML CR2/CRp2 |
| TBPH | Theravance Biopharma, Inc. | 2024-12-01 | Phase 3 | NCT05696717 | Phase 3 Efficacy and Durability of Ampreloxetine for the Treatment of Symptomatic NOH in Participants with Multiple System Atrophy |
| VNDA | Vanda Pharmaceuticals Inc. | 2024-12-01 | Phase 3 | NCT04028492 | Evaluating the Safety and Efficacy of Tradipitant vs. Placebo in Idiopathic and Diabetic Gastroparesis |
| VRDN | Viridian Therapeutics, Inc. | 2024-12-01 | Phase 3 | NCT06021054 | An Efficacy, Safety, and Tolerability Study of Veligrotug (VRDN-001), in Participants with Chronic Thyroid Eye Disease (TED) (THRIVE-2) |
| VRNA | Verona Pharma plc | 2024-12-01 | Phase 3 | NCT06460493 | Effect of Ensifentrine Treatment on CAT Score |
| XFOR | X4 Pharmaceuticals, Inc. | 2024-12-01 | Phase 3 | NCT03995108 | Efficacy and Safety Study of Mavorixafor in Participants With Warts, Hypogammaglobulinemia, Infections, and Myelokathexis (WHIM) Syndrome |